Taken together, these results corroborate our hypothesis that Pml is able to sustain leukemic cells non-cell autonomously, and suggest that coupling chemotherapy treatment with AS2O3, or other Pml inhibitors could be beneficial in the treatment of several subgroups of leukemia, including certain types of AML, through the niche. This evidence concerns the gene PML and leukemia.